217 related articles for article (PubMed ID: 3603409)
1. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
[TBL] [Abstract][Full Text] [Related]
2. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
[TBL] [Abstract][Full Text] [Related]
3. Homozygous variant of antithrombin III: AT III Fontainebleau.
Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
[TBL] [Abstract][Full Text] [Related]
4. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
Tran TH; Bondeli C; Marbet GA; Duckert F
Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin III Alger: a new homozygous AT III variant.
Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M
Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
Tripodi A; Krachmalnicoff A; Mannucci PM
Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.
Howarth DJ; Samson D; Stirling Y; Seghatchian MJ
Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
Jørgensen M; Petersen LC; Thorsen S
J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville.
Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN
Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951
[TBL] [Abstract][Full Text] [Related]
10. Homozygous or compound heterozygous qualitative antithrombin III deficiency.
Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256
[TBL] [Abstract][Full Text] [Related]
11. AT III Barcelona: a familial quantitative-qualitative AT III deficiency.
Grau E; Fontcuberta J; Félez J; de Diego I; Soto R; Rutllant ML
Thromb Haemost; 1988 Feb; 59(1):13-7. PubMed ID: 3363529
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
[TBL] [Abstract][Full Text] [Related]
13. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
[TBL] [Abstract][Full Text] [Related]
14. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.
Sas G; Blaskó G; Bánhegyi D; Jákó J; Pálos LA
Thromb Diath Haemorrh; 1974 Sep; 32(1):105-15. PubMed ID: 4454033
[TBL] [Abstract][Full Text] [Related]
15. Abnormal properties and behaviors of antithrombin III found in a thrombophilic patient: defective biological functions and dissimilar antigenic determinants.
Murayama H; Matsuda M
Thromb Haemost; 1986 Oct; 56(2):165-71. PubMed ID: 3101219
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
Shimotori T; Sakuragawa N
Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin III Padua: a "new" congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease.
Girolami A; Pengo V; Cappellato G; Vianello C; Procidano M; Cartei C
Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(1):98-111. PubMed ID: 6192061
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
20. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
Chan TK; Chan V
Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
